InMode Ltd.
INMDHealthcareNASDAQMedical Devices
Scan Results
Daily timeframeHeadquartered within the healthcare sector, InMode Ltd. focuses on Medical Devices services and products. InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radio frequency assisted lipolysis and deep subdermal fractional radiofrequency. The $889.2M market capitalization puts INMD squarely in small-cap range for its industry. It offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.
Market Cap
$889.2M
Beta
1.91
P/E (TTM)
11.54
P/E (Fwd)
10.68
EPS (TTM)
$1.34
EPS (Fwd)
$1.45
ROE
13.6%
ROA
6.9%
Cash
$537.2M
Total Debt
$4.8M
Free CF
$43.6M
52W Change
11.3%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $537.2M in cash comfortably exceeding the $4.8M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Annual free cash flow of $43.6M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. ROE of 13.6% points to decent capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. An ROA of 6.9% suggests reasonable efficiency in deploying the company's asset base. Revenue has pulled back from $454.3M (2022) to $370.5M (2025), a 18% decline worth watching.
InMode Ltd.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence InMode Ltd.'s trajectory.